Treatment With Oxymorphone Is Patent-Eligible, Panel Says

Mealey's (April 2, 2019, 1:33 PM EDT) -- WASHINGTON, D.C. — In a March 28 ruling, the Federal Circuit U.S. Court of Appeals found that a Delaware federal judge incorrectly deemed a method of administering controlled release oxymorphone to treat pain in patients with impaired kidney function ineligible for patenting under Section 101 of the Patent Act (Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals Inc., et al., Nos. 2017-1240, -1455, -1887, Fed. Cir., 2019 U.S. App. LEXIS 9189)....